Vegzelma

Bio & Pharma Celltrion expands footprint in Latin America with flagship oncology drugs

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...

Bio & Pharma Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe

South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...

Bio & Pharma Celltrion to export three anticancer drugs to Europe

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...

Bio & Pharma Celltrion’s Vegzelma listed on US PBM preferred drug list

South Korea's Celltrion Healthcare Co. announced on Tuesday that its anti-cancer biosimilar Vegzelma (active ingredient: bevacizumab) was listed as ...

Bio & Pharma Celltrion’s Vegzelma listed on prescription of 10 private US insurers

South Korea’s Celltrion Healthcare Co. announced on Wednesday that it has signed contracts with 10 insurance providers in the US to boost the ...

Bio & Pharma S.Korea's Celltrion Healthcare launches Vegzelma in US

South Korea's Celltrion Healthcare Co. on Monday said it launched on the US market Vegzelma, a biosimilar of Bevacizumab, a medication for colorecta...

Bio & Pharma Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan

Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizum...

Bio & Pharma Celltrion acquires approval to sell Vegzelma in Canada

South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma...

Bio & Pharma Celltrion's Remsima receives approval in 100 countries in 10 years

South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...

Bio & Pharma Celltrion wins sales approval for biosimilar Vegzelma in Japan

Celltrion Inc. secured Japan’s approval for sales of its cancer treatment biosimilar CT-P16, a move to help the South Korean biopharmaceutical...

Bio & Pharma Celltrion gains sales approval for biosimilar Vegzelma in Europe

Celltrion Healthcare Co., South Korean biopharmaceutical giant Celltrion Inc.'s global marketing affiliate, said on Friday it has obtained the Europ...